Evidence map›Paper›PMID 34215697›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Matrix lumican endocytosed by immune cells controls receptor ligand trafficking to promote TLR4 and restrict TLR9 in sepsis.

George Maiti, Jihane Frikeche, Carly Yuen-Man Lam, Asim Biswas, Vishal Shinde, Marie Samanovic, Jonathan C Kagan, Mark J Mulligan, Shukti Chakravarti

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. [Menstrual blood-derived mesenchymal stem cell transplantation improves anti-fibrosis mechanisms in mouse models of alcoholic liver fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  5. Review
  6. Sulfated Glycosaminoglycans in Inflammation.Advances in experimental medicine and biology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Paracrine regulations of IFN-γ secreting CD4Matrix biology : journal of the International Society for Matrix Biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

George MaitiDepartment of Ophthalmology, New York University Grossman School of Medicine, New York, NY 10016.ORCID 0000-0002-6701-5499
Jihane FrikecheDivision of Preclinical Pharmacology and Safety, Sangamo Therapeutics, Valbonne 06560, France.ORCID 0000-0003-1291-6908
Carly Yuen-Man LamDepartment of Ophthalmology, New York University Grossman School of Medicine, New York, NY 10016.ORCID 0000-0002-2593-7719
Asim BiswasDepartment of Ophthalmology, New York University Grossman School of Medicine, New York, NY 10016.ORCID 0000-0002-4999-4697
Vishal ShindeDepartment of Ophthalmology, New York University Grossman School of Medicine, New York, NY 10016.ORCID 0000-0002-9110-1979
Marie SamanovicLangone Vaccine Center, New York University, New York, NY 10016.ORCID 0000-0002-6987-2232
Jonathan C KaganHarvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA 02115.ORCID 0000-0003-2364-2746
Mark J MulliganLangone Vaccine Center, New York University, New York, NY 10016.
Shukti ChakravartiDepartment of Ophthalmology, New York University Grossman School of Medicine, New York, NY 10016; shukti.chakravarti@nyumc.org.ORCID 0000-0001-7543-1903
New York University · USNYU Langone Health · USBoston Children's Hospital · US

Funding

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9M
The Role of Lumican in the CorneaR01EY011654 · NEI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHAKRAVARTI, SHUKTI · 1997 to 2017
$6.1M
Extracellular matrix proteoglycans regulate toll-like receptors 4 and 9 - Equipment SupplementR01EY030917 · NEI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHAKRAVARTI, SHUKTI · 2020 to 2023
$1.8M
The Role of Lumican in the corneaR56EY011654 · NEI · JOHNS HOPKINS UNIVERSITY · PI CHAKRAVARTI, SHUKTI · 2007 to 2007
$474k
NEI NIH HHS R01 EY011654NEI NIH HHS R01 EY030917NEI NIH HHS R56 EY011654NIAID NIH HHS UM1 AI148574
6 · The paper itself

Abstract

Infections and inflammation are profoundly influenced by the extracellular matrix (ECM), but their molecular underpinnings are ill defined. Here, we demonstrate that lumican, an ECM protein normally associated with collagens, is elevated in sepsis patients' blood, while lumican-null mice resolve polymicrobial sepsis poorly, with reduced bacterial clearance and greater body weight loss. Secreted by activated fibroblasts, lumican promotes Toll-like receptor (TLR) 4 response to bacterial lipopolysaccharides (LPS) but restricts nucleic acid-specific TLR9 in macrophages and dendritic cells. The underlying mechanism involves lumican attachment to the common TLR coreceptor CD14 and caveolin 1 (Cav1) in lipid rafts on immune cell surfaces via two epitopes, which may be cryptic in collagen-associated lumican. The Cav1 binding epitope alone is sufficient for cell surface enrichment of Cav1, while both are required for lumican to increase cell surface TLR4, CD14, and proinflammatory cytokines in response to LPS. Endocytosed lumican colocalizes with TLR4 and LPS and promotes endosomal induction of type I interferons. Lumican-null macrophages show elevated TLR9 in signal-permissive endolysosomes and increased response, while wild types show lumican colocalization with CpG DNA but not TLR9, consistent with a ligand sequestering, restrictive role for lumican in TLR9 signaling. In vitro, lumican competes with CD14 to bind CpG DNA; biglycan, a lumican paralog, also binds CpG DNA and suppresses TLR9 response. Thus, lumican and other ECM proteins, synthesized de novo or released from collagen association during ECM remodeling, may be internalized by immune cells to regulate their transcriptional programs and effector responses that may be harnessed in future therapeutics.

Indexed as

EndocytosisAdultAnimalsCaveolin 1Cell MembraneDisease Models, AnimalEndosomesExtracellular MatrixFibroblastsHEK293 CellsHumansLeukocytesLigandsLipopolysaccharide ReceptorsLumicanMacrophagesCaveolin 1CPG-oligonucleotideLigandsLipopolysaccharide ReceptorsLumicanMyeloid Differentiation Factor 88OligodeoxyribonucleotidesToll-Like Receptor 4Toll-Like Receptor 9inflammationlumicanmacrophagesepsisTLR

Identifiers

PMID34215697
PMCPMC8271568
OpenAlexW3177218861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.